Document is current
Any future updates will be listed below
-
Authors
Wada, Masataka https://orcid.org/0000-0002-3937-3619
Nakajima, Shinichiro https://orcid.org/0000-0002-2601-2195
Honda, Shiori
Takano, Mayuko
Taniguchi, Keita https://orcid.org/0009-0002-0643-8452
Homma, Saki
Ueda, Risako
Tobari, Yui
Mimura, Yu
Fujii, Shinya
Mimura, Masaru
Noda, Yoshihiro https://orcid.org/0000-0002-2155-0357
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (18K15375)
MEXT | Japan Society for the Promotion of Science (20K16503)
- License Information
-
More Information
Article History
Received: 10 August 2023
Revised: 13 November 2024
Accepted: 19 November 2024
First Online: 25 November 2024
Competing interests
: SH, MT, KT, SH, RU, NH, and YT have no actual or potential conflicts of interest. MW has received grants from the Japan Society for the Promotion of Science (20K16503) and the Takeda Science Foundation. He has received a fellowship Nakatani Foundation. He has also received manuscript fees or speaker’s honoraria from Dainippon Sumitomo Pharma, Eisai, and Takeda Pharmaceutical Co. Ltd. Within the past three years. SN has received grants from the Japan Society for the Promotion of Science (18H02755 and 22H03002), the Japan Agency for Medical Research and Development (AMED), the Japan Research Foundation for Clinical Pharmacology, the Naito Foundation, the Takeda Science Foundation, the Watanabe Foundation, the Uehara Memorial Foundation, and the Daiichi Sankyo Scholarship Donation Program within the past three years. He has also received research support, manuscript fees, or speaker’s honoraria from Dainippon Sumitomo Pharma, Meiji-Seika Pharma, Otsuka Pharmaceutical, Shionogi, and Yoshitomi Yakuhin within the past three years. SF has received a Grant-in-Aid for Young Scientists B (16K16483) and Grants-in-Aid for Scientific Research B (20H04092) from JSPS and research grants from Keio University Academic Development Funds. YM has received grants from the Japan Society for the Promotion of Science (20K16677) and Eisai. MM has received speaker’s honoraria from Byer Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, Fuji Film RI Pharma, Hisamitsu Pharmaceutical, Janssen Pharmaceutical, Kyowa Pharmaceutical, Mochida Pharmaceutical, MSD, Mylan EPD, Nihon Medi-physics, Nippon Chemipher, Novartis Pharma, Ono Yakuhin, Otsuka Pharmaceutical, Pfizer, Santen Pharmaceutical, Shire Japan, Takeda Yakuhin, Tsumura, and Yoshitomi Yakuhin within the past three years. Also, he received grants from Daiichi Sankyo, Eisai, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi, and Tsumura within the past three years outside the submitted work. YN has received a Grant-in-Aid for Scientific Research (B) (21H02813) from the Japan Society for the Promotion of Science (JSPS), research grants from the Japan Agency for Medical Research and Development (AMED), investigator-initiated clinical study grants from Teijin Pharma Ltd. And Inter Reha Co., Ltd. He has also received research grants from the Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Taiju Life Social Welfare Foundation, and Daiichi Sankyo Scholarship Donation Program. He has received speaker’s honoraria from Dainippon Sumitomo Pharma, Mochida Pharmaceutical Co., Ltd., Yoshitomiyakuhin Corporation, Qol Co., Ltd., Teijin Pharma Ltd., Takeda Pharmaceutical Co., Ltd., and Lundbeck Japan Co. Ltd. Within the past five years outside the submitted work. He also receives equipment-in-kind support for an investigator-initiated study from Magventure Inc., Inter Reha Co., Ltd., Brainbox Ltd., and Miyuki Giken Co., Ltd.
